Etilevodopa HCl (TV-1203; Levodopa ethyl ester; L-Dopa ethyl ester; O-Ethyl-DOPA), the hydrochloride salt of Etilevodopa, is a dopaminergic agent used for the treatment for Parkinson's disease. It is an ethyl-ester prodrug of levodopa that has greater gastric solubility, passes quickly into the small intestine, is rapidly hydrolyzed to levodopa, and has a shortened time to maximum levodopa concentration.

Physicochemical Properties

Molecular Formula	C11H16CLNO4
Molecular Weight	261.702
Exact Mass	261.077
CAS #	39740-30-2
Related CAS #	Etilevodopa;37178-37-3
PubChem CID	12485237
Appearance	Light yellow to yellow solid powder
LogP	2.033
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	5
Heavy Atom Count	17
Complexity	234
Defined Atom Stereocenter Count	1
SMILES	CCOC(=O)[C@H](CC1=CC(=C(C=C1)O)O)N.Cl
InChi Key	CVQFXVIIFKVRCK-QRPNPIFTSA-N
InChi Code	InChI=1S/C11H15NO4.ClH/c1-2-16-11(15)8(12)5-7-3-4-9(13)10(14)6-7;/h3-4,6,8,13-14H,2,5,12H2,1H3;1H/t8-;/m0./s1
Chemical Name	ethyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate;hydrochloride
Synonyms	TV-1203 HClL-Dopa ethyl ester Levodopa ethyl ester TV1203 Etilevodopa
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage.(2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro

After traveling through the stomach unaltered, ativodopa (levodopa ethyl ester) hydrochloride enters the duodenum, where local esterase quickly hydrolyzes it into levodopa and ethanol, which is then quickly absorbed into the bloodstream as levodopa. Stream [1]. Azidovopa hydrochloride is more soluble in the stomach, enters the small intestine more quickly, and achieves the maximum levodopa concentration in less time when compared to regular levodopa [2].

References

[1]. Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. Clin Neuropharmacol. 2003 Nov-Dec;26(6):322-6. [2]. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol. 2006 Feb;63(2):210-6. [3]. Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease. Molecules. 2017 Dec 25;23(1). pii: E40.

Solubility Data

Solubility (In Vitro)	H2O : ~125 mg/mL (~477.65 mM)
Solubility (In Vivo)	Solubility in Formulation 1: 25 mg/mL (95.53 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.8212 mL	19.1058 mL	38.2117 mL
	5 mM	0.7642 mL	3.8212 mL	7.6423 mL
	10 mM	0.3821 mL	1.9106 mL	3.8212 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.